JAC Advance Access originally published online on February 22, 2005
Journal of Antimicrobial Chemotherapy 2005 55(4):535-541; doi:10.1093/jac/dki026
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes
1 School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033; 2 Department of Pharmacy, Huntington Hospital, Pasadena, CA; 3 College of Pharmacy, Western University, Pomona, CA; 4 Department of Hospital Epidemiology, UCLA David Geffen School of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
* Corresponding author. Tel: +1-323-442-1356; Fax: +1-626-628-3024; Email: anniew{at}usc.edu
Objectives: Resistance among Pseudomonas aeruginosa has risen dramatically and parallels the increase in fluoroquinolone (FQ) prescribing in recent years. Risk factors for FQ resistance in P. aeruginosa and its impact on outcomes need to be well characterized.
Methods: A case–control study was carried out on hospitalized adult patients from whom FQ-resistant (case) and FQ-susceptible (control) P. aeruginosa were isolated.
Results: A total of 177 patients with positive cultures (91 cases and 86 controls) and 119 with documented infections (65 cases, 54 controls) were included in risk factor and outcomes analysis, respectively. Independent risk factors for FQ resistance were: FQ exposure (OR 12.6, CI 4.95–32), nosocomial acquisition (OR 8.6, CI 3.5–20.7), and diabetes mellitus (OR 6.4, CI 2.1–19.3). An FQ agent was prescribed in 59% of patients receiving an ‘antipseudomonal’ empirical regimen. Compared with controls, FQ-resistant cases had a median delay to receiving effective therapy of 3.5 days versus 1 day and poorer outcomes: (i) lower complete response rate (45% versus 63%, P=0.04); (ii) longer time to achieve clinical stability (8 days versus 3 days, P=0.005); and (iii) higher infection-related mortality (21% versus 7%; OR = 2.9, 0.9–9.4). Empirical FQ use (OR 4.6, CI 1.5–14.3), FQ resistance (OR 3.6, CI 1.0–13.1), and high APACHE II score (OR 1.1, CI 1.0–1.2) were independent risk factors for increased mortality.
Conclusions: FQ exposure from widespread prescribing is a modifiable risk factor for FQ resistance in P. aeruginosa. FQ empirical therapy for Pseudomonas infections may be associated with significant delays in administering effective therapy resulting in adverse outcomes.
Keywords: levofloxacin , empirical prescribing , multidrug resistance , mortality
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. A. Wargo, B. M. Wright, and R. Gupta The Utility of Fluoroquinolones in the Critically Ill Journal of Pharmacy Practice, October 1, 2008; 21(5): 346 - 355. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Patel, L.-A. McNutt, and T. P. Lodise Relationship between Various Definitions of Prior Antibiotic Exposure and Piperacillin-Tazobactam Resistance among Patients with Respiratory Tract Infections Caused by Pseudomonas aeruginosa Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2933 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Nguyen, D. I. Hsu, V. Ganapathy, K. Shriner, and A. Wong-Beringer Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome J. Antimicrob. Chemother., March 1, 2008; 61(3): 714 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pena, A. Guzman, C. Suarez, M. A. Dominguez, F. Tubau, M. Pujol, F. Gudiol, and J. Ariza Effects of Carbapenem Exposure on the Risk for Digestive Tract Carriage of Intensive Care Unit-Endemic Carbapenem-Resistant Pseudomonas aeruginosa Strains in Critically Ill Patients Antimicrob. Agents Chemother., June 1, 2007; 51(6): 1967 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-Y Wang, P-R Hsueh, I-S Jan, L-N Lee, Y-S Liaw, P-C Yang, and K-T Luh Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas Thorax, October 1, 2006; 61(10): 903 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Kaye, Z. A. Kanafani, A. E. Dodds, J. J. Engemann, S. G. Weber, and Y. Carmeli Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2192 - 2196. [Abstract] [Full Text] [PDF]
|
|